Search Tag: ESC Congress 2019
2019 03 Sep
At the ESC Congress this year, several new guidelines have been released including updated guidelines on lipid control and new guidelines on diabetes and cardiovascular disease. As per the updated guidelines on lipid control , the following are some key recommendations: Low-density lipoprotein (LDL) cholesterol levels should be lowered...Read more
2019 01 Sep
The DAPA-HF study findings were presented today by Dr. John McMurray at the ESC Congress in Paris. DAPA-HF is an international, multi-centre, parallel-group, randomised, double-blind trial in patients with heart failure and reduced ejection fraction (LVEF = 40%), with and without type-2 diabetes, designed to evaluate the effect of dapagliflozin,...Read more
2019 01 Sep
Investigators from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris presented the results from The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS) study at the ESC Congress in Paris. The THEMIS trial evaluated whether adding ticagrelor to aspirin improved...Read more
2019 31 Aug
New findings from the CHAT-DM study presented at the ESC Congress today report that text message intervention can result in better glycaemic control in patients with diabetes mellitus and coronary heart disease. Findings were just published in Circulation: Cardiovascular Quality and Outcomes. According to the study author Dr. Xiqian Huo of...Read more
2019 31 Aug
Despite the fact that guidelines recommend the initiation of high-intensity statin therapy in patients with acute coronary syndrome (ACS), target levels are not achieved in a large number of patients. Evolocumab, a rapidly acting, low-density lipoprotein cholesterol (LDL-C) Lowering drug had so far not been studied in the acute phase of acute coronary...Read more
2019 29 Aug
ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2019 together with the World Congress of Cardiology takes place from 31 August to 4 September at the Expo Porte de Versailles in Paris, France. The ESC Congress...Read more
2019 10 Aug
Topline findings from the Phase III PARAGON-HF study have just been announced. Full results of the trial will be presented at the ESC Congress 2019 in September. The PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFPEF) investigates the safety and efficacy of sacubitril/valsartan versus the active comparator...Read more
2019 03 Aug
Topline findings from the Phase III PARAGON-HF study have just been announced. Full results of the trial will be presented at the ESC Congress 2019 in September. The PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFPEF) investigates the safety and efficacy of sacubitril/valsartan versus the active comparator...Read more
2019 31 Aug
Find European Society of Cardiology on Social Media Find WCC - World Heart Federation on Social Media Read more